Corvas International Incorporated

Corvas International, Inc. is a biopharmaceutical company focused on development of a new generation of drugs that address today's largest medical markets, cardiovascular disease and cancer, based on our expertise in vascular biology and protease modulation. We have a strategic alliance with Pfizer Inc for the development and commercialization of our novel anti-inflammatory agent (rNIF or UK-279,276) to treat ischemic stroke. Completion of patient recruitment into the Phase IIb clinical trial of UK-279,276 was recently announced with results expected in mid-2002. We expect to initiate a Phase IIb clinical trial for the treatment of unstable angina in 2002 with our potent anticoagulant rNAPc2. Our cancer drug discovery programs are focused on the development of therapeutic drugs that modulate the activity of serine proteases associated with the growth and progression of solid tumors through the use of innovative chemistry and biology-based platform technologies. We have developed our portfolio of drug candidates by integrating an in-depth knowledge of serine protease inhibition and the biology of thrombosis and, more generally, vascular biology with advanced and proprietary drug discovery and design technology.

Contact Details: 3030 Science Park Road San Diego CA 92121 United States of America Tel: 858 455 9800 Fax: Email: ir@corvas.com WWW: www.corvas.com/

Loading...

Recent Publications by Corvas International Incorporated:
Antiparasitic agents. Parasitic diseases predominantly affect the developing world because of...	4th October, 2005	Corvas International, 3030 Science Park Road, San Diego, California 92307,	IDrugs. 1998 Dec;1(8):843-5.
Binding of nonphysiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis. Understanding the regulation of physiological processes requires detailed...	25th June, 2003	Department of Molecular Biology, Corvas International, 3030 Science Park	Biochemistry. 2003 May 13;42(18):5395-402. DOI Direct Link
Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Recombinant nematode anticoagulant protein c2 (rNAPc2) is a potent (K(i) =...	13th March, 2003	Corvas International, Inc., San Diego, California 92121, USA.	Trends Cardiovasc Med. 2002 Nov;12(8):325-31.
Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates. Novel, potent, and highly selective classes of thrombin inhibitors were...	12th March, 2003	Department of Medicinal Chemistry, Corvas International, Inc., 3030	Bioorg Med Chem Lett. 2002 Oct 21;12(20):2925-30.
Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. Investigations on P(2)-P(3)-heterocyclic dipeptide surrogates directed...	3rd October, 2002	Department of Medicinal Chemistry, Corvas International, Inc., 3030	Bioorg Med Chem Lett. 2002 Apr 22;12(8):1203-8.
→View more Corvas International Incorporated research publications.

BioNews Results for Corvas International Incorporated:
Chinese Fosun Pharma rises on acquisition deal	China Securities Journal Net:  Nov 22 2009 3:56PM Matching: international
Hong Kong (China), 4th-5th January 2010: The 3rd International Conference on Ethics and Policy of Biometrics a	IPR Helpdesk:  Nov 22 2009 9:19AM Matching: international
HealthyKids International to raise much-needed funds for SickKids Global Child Health Program	CNW Telbec:  Nov 21 2009 12:06AM Matching: international
Stocks That Stand Out For Nov. 20th, 2009 Are ARTS, RFMD, CLDS, ACTC	Pharmacy Choice:  Nov 21 2009 1:27PM Matching: international
Huge Stock News Alert On - (OTCBB:BRGO) - (OTCBB:GETA) - (OTCBB:ARTS)	Pharmacy Choice:  Nov 21 2009 1:15AM Matching: international
Promote your company here: BioNewsCast - Press Release Distribution	→View more Corvas International Incorporated news.

Corvas International Incorporated Patents:
US Patent No.	Title
5747449	Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
5886146	Inhibitors of thrombosis
5919900	Modified hookworm neutrophil inhibitors
5932733	3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
5945275	Nematode-extracted anticoagulant protein
→View more Corvas International Incorporated patents.

Corvas International Incorporated (CVAS) Financial information Links from Barchart
CVAS Quote from from Barchart.com
CVAS Chart from from Barchart.com
CVAS Profile from from Barchart.com
CVAS Opinion from from Barchart.com
→View more Corvas International Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 753 times since April 2007, the link to the organisation's website has been followed 169 times

Recent Search Terms used to find this page: corvas international san diego | Corvas International | Corvas International Inc | Corvas International Inc. | Corvas Internationa | corvas international | corvas international inc. | Corvas novel anti-inflammatory agent | corvas international | corvas international | .

Search for more companies in San Diego

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Corvas International Incorporated